Publications by authors named "Ke Cheng Xu"

Background: Bronchial cysts are congenital malformations usually located in the mediastinum, and intrapulmonary localization is very rare. Cryoablation is a novel therapeutic approach that promotes tumor necrosis and stimulates anti-tumor immune responses.

Case Summary: This article reports a case of a 68-year-old male patient who was diagnosed with an intrapulmonary bronchogenic cyst by computed tomography examination and pathology, and the patient subsequently underwent cryoablation therapy and achieved complete response with after 3 months of follow-up.

View Article and Find Full Text PDF

Introduction: This study aimed to identify the pathogen responsible for leaf blight in , investigate its biological characteristics, and identify effective synthetic fungicides. Additionally, this study examined changes in physiological and biochemical indices of leaves following pathogen infection and screened biocontrol bacteria that inhibit the pathogen growth, providing a scientific basis for preventing and managing leaf blight in .

Methods: Pathogens were isolated from the interface of healthy and infected leaf tissues and identified through morphological and molecular biological methods.

View Article and Find Full Text PDF

Following standard treatments, the traditional model for enhancing anti-tumor immunity involves performing immune reconstitution (e.g., adoptive immune cell therapies or immunoenhancing drugs) to prevent recurrence.

View Article and Find Full Text PDF

The use of hydrogen for cancer control has made great progress in cytology and animal experiments. With the increasing number of hydrogen products on the market, larger numbers of advanced cancer patients have participated in clinical trials or received treatment at home after purchase. Our study reported a real-world survey from 82 patients with good cancer control using hydrogen products, including real world evidence from patients who received ineffective traditional treatment, patients who received traditional treatment that failed, or patients who refused traditional treatment.

View Article and Find Full Text PDF

Chemotherapy, targeted therapy, and immunotherapy are used against advanced non-small cell lung cancer. A clinically efficacious method for relieving the adverse events associated of such therapies is lacking. Fifty-eight adult patients were enrolled in our trial to relieve pulmonary symptoms or the adverse events of drugs.

View Article and Find Full Text PDF

Advanced cancer treatment is a huge challenge and new ideas and strategies are required. Hydrogen exerts antioxidant and anti-inflammatory effects that may be exploited to control cancer, the occurrence and progression of which is closely related to peroxidation and inflammation. We conducted a prospective follow-up study of 82 patients with stage III and IV cancer treated with hydrogen inhalation using the "real world evidence" method.

View Article and Find Full Text PDF
Article Synopsis
  • A 72-year-old woman with gallbladder cancer (GBC) experienced disease progression and metastases after initial treatments, including chemotherapy and electroporation ablation.
  • She developed severe anemia and intestinal complications from tumor invasion but refused further conventional treatments.
  • After starting daily hydrogen inhalation therapy, the patient saw improvements, including reduced tumor size, corrected anemia, and an overall stabilization of her health, enabling her to resume normal activities.
View Article and Find Full Text PDF

We used circulating tumor cells (CTCs) as biomarkers to evaluate the efficacy of pre-irreversible electroporation (IRE) and post-IRE for unresectable pancreatic cancer (PC). Real-time qPCR was used to detect potential biomarker genes in CTCs, and magnetic-activated cell sorting (MACS) and fluorescence-activated cell sorting (FACS) were performed on 43 patients with PC who underwent IRE. Some patients experienced adverse reactions within 30 days of the operation, including arrhythmia (6.

View Article and Find Full Text PDF

Aberrantly expressed microRNAs contribute to the initiation and progression of human cancer. MiRNA-187 has been reported in nasopharyngeal, renal, pancreatic, prostate, and esophageal cancer, and acts as a tumor suppressor or oncogene. However, the underlying function of miRNA-187 in cervical cancer remains largely unexplored.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on measuring circulating tumor cells (CTCs) in stage IV non-small cell lung cancer (NSCLC) patients before and after natural killer (NK) cell therapy to assess how these changes relate to treatment effectiveness.
  • CTC counts were taken from 31 patients at three time points: one day before, and seven and thirty days after NK therapy, revealing a significant decrease in CTCs over time.
  • Gene expression levels of CTC-related markers like CEA, MAGE-3, and CK18 were also assessed, showing significant increases after NK therapy and decreases over time, suggesting CTCs can serve as an important biomarker for NK therapy effectiveness in NSCLC.
View Article and Find Full Text PDF

In this study, the safety and clinical efficacy of cryosurgery combined with allogenic NK cell immunotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) were evaluated. From July 2016 to March 2017, we enrolled 60 patients who met the enrollment criteria and divided them into two groups: (1) the simple cryoablation group (n = 30) and (2) the cryoablation combined with allogenic NK cell group (n = 30). The changes in immune function, quality of life, and clinical response were evaluated.

View Article and Find Full Text PDF

Percutaneous cryoablation under imaging guidance has been proved to be a safe and effective method for ablation and debulking of tumors, providing radical cure or palliation, as the case may be, for patients with different stages of disease. The local control rate is high with cryoablation, and the complications are usually controllable, making it a reasonable choice in lung cancer treatment. In this paper the technique and mechanism of action of cryoablation are summarized, and studies performed on the application of percutaneous cryoablation in various stages of lung cancer are reviewed.

View Article and Find Full Text PDF

This study aimed to investigate the safety and effectiveness of irreversible electroporation ablation for unresectable large liver cancer. Fourteen patients were enrolled: 8 with large hepatocellular carcinoma (tumor diameter: 5.1-11.

View Article and Find Full Text PDF
Article Synopsis
  • Pancreatic carcinoma is a serious and aggressive cancer with a poor outlook, typically diagnosed too late for surgical intervention.
  • Radical surgery is the only curative option, but many patients are not candidates, and chemotherapy and radiotherapy are largely ineffective.
  • Cryoablation, a minimally invasive palliative treatment, shows promise for patients with advanced or unresectable pancreatic cancer, particularly when combined with other therapies, suggesting potential improvements in survival outcomes.
View Article and Find Full Text PDF

Based on the primary tumor site, liver cancer can be divided into two categories: (1) primary liver cancer and (2) metastatic cancer to the liver from a distant primary site. Guided cryoablation via many imaging methods induces iceball formation and tumor necrosisand is an attractive option for treating unresectable hepatocellular carcinoma (HCC) and metastatic liver cancer. There are several advantages to using cryoablation for the treatment of liver cancer: it can be performed percutaneously, intraoperatively, and laparoscopically; iceball formation can be monitored; it has little impact on nearby large blood vessels; and it induces a cryo-immunological response in situ.

View Article and Find Full Text PDF

Introduction: In this trial, we isolated and cultured pancreatic cancer stem cells (CSCs) to produce a vaccine and prospectively evaluated its safety and efficacy in low-, medium-, and high-dose groups.

Material And Methods: Between February and October 2014, we enrolled 90 patients who met the enrollment criteria and assigned them to three groups (n = 30). CSC-specific and CSC-non-specific immunity pre- and post-vaccination were compared by Dunnett's multiple comparison test (one-way ANOVA).

View Article and Find Full Text PDF

In this trial, lung cancer stem cells (CSCs) were separated and cultured to produce a vaccine; its safety and efficacy were prospectively evaluated in low-, medium-, and high-dose groups. Between February and September 2014, we enrolled 90 patients who met the enrollment criteria and assigned them to three groups (n = 30). Throughout the trial, injection site reaction was the most common reaction (63 %), and fever was least common (16 %); however, there was no difference among the three groups.

View Article and Find Full Text PDF

Aim: To retrospectively assess the effect of comprehensive cryosurgery (ablation of intra- and extra-hepatic tumors) plus dendritic cell-cytokine-induced killer cell immunotherapy in metastatic hepatocellular cancer.

Methods: We divided 45 patients into cryo-immunotherapy (21 patients), cryotherapy (n = 12), immunotherapy (n = 5) and untreated (n = 7) groups. Overall survival (OS) after diagnosis of metastatic hepatocellular cancer was assessed after an 8-year follow-up.

View Article and Find Full Text PDF

Aim: To study the effect and tolerance of intraperitoneal perfusion of cytokine-induced killer (CIK) cells in combination with local radio frequency (RF) hyperthermia in patients with advanced primary hepatocellular carcinoma (HCC).

Methods: Patients with advanced primary HCC were included in this study. CIK cells were perfused intraperitoneal twice a week, using 3.

View Article and Find Full Text PDF

Fine-needle aspiration biopsy is a method to detect malignancy for undetermined pulmonary nodules, but has the potential to spread malignant cells from the tumor to the pleural cavity or chest wall. We developed a two-step freezing method to avoid needle-tract seeding, by use of percutaneous cryoablation after biopsy but before the biopsy needle was removed. A man aged 72 years was admitted because of a large mass in right upper lobe.

View Article and Find Full Text PDF

Objective: To assess the efficacy and safety of percutaneous cryoablation (PCC) and (125)I seed implantation combined with chemotherapy for advanced pancreatic cancer.

Methods: Sixty-seven patients with advanced pancreatic cancer (6 in stage III, 61 in stage IV) received PCC and (125)I seed implantation combined with concomitant gemcitabine hydrochloride and DDP chemotherapy. The clinical benefit response (CBR), survival rate and therapy-related complications were assessed.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness of radical versus palliative treatments in stage IV pancreatic cancer patients, involving 81 participants.
  • Radical treatment was associated with significantly longer interval survival compared to palliative treatment.
  • The timing and number of treatments also influenced outcomes, with multiple radical treatments being beneficial, while the same did not apply to palliative care.
View Article and Find Full Text PDF

Aim: To evaluate the efficacy of sequential use of transarterial chemoembolization (TACE) and percutaneous cryosurgery for unresectable hepatocellular carcinoma (HCC).

Methods: Four hundred and twenty patients were enrolled in this study. The patients, who were considered to have unresectable tumors due to their location or size or comorbidity, were divided into sequential TACE-cryosurgery (sequential) group (n = 290) and cryosurgery alone (cryo-alone) group (n = 130).

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the effectiveness of combining cryosurgery with (125) iodine seed implantation for treating locally advanced pancreatic cancer in 49 patients.
  • The treatment involved either intraoperative or percutaneous cryosurgery, followed by (125) iodine seed implantation, with some patients also receiving regional chemotherapy.
  • Results showed significant tumor necrosis in most patients, with complete response in 20.4%, partial response in 38.8%, and a median survival of 16.2 months, indicating a promising therapeutic approach without therapy-related mortality.
View Article and Find Full Text PDF